Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Dosimetry study of [I-131] and [I-125]- meta-iodobenz guanidine in a simulating model for neuroblastoma metastasis.

Roa WH, Yaremko B, McEwan A, Amanie J, Yee D, Cho J, McQuarrie S, Riauka T, Sloboda R, Wiebe L, Loebenberg R, Janicki C.

Technol Cancer Res Treat. 2013 Feb;12(1):79-90. doi: 10.7785/tcrt.2012.500301. Epub 2012 Sep 15.

PMID:
22974332
2.
3.

131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.

Gaze MN, Mairs RJ, Boyack SM, Wheldon TE, Barrett A.

Br J Cancer. 1992 Dec;66(6):1048-52.

4.

Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.

Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST.

Cancer Biother Radiopharm. 2005 Apr;20(2):195-9.

PMID:
15869455
5.

Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.

Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, Hawkins RA, Veatch J, Hasegawa B.

J Nucl Med. 2001 Nov;42(11):1713-21.

6.

Targeted radiotherapy of multicell neuroblastoma spheroids with high specific activity [125I]meta-iodobenzylguanidine.

Roa WH, Miller GG, McEwan AJ, McQuarrie SA, Tse J, Wu J, Wiebe LI.

Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):425-32.

PMID:
9607361
7.

Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.

Rutgers M, Buitenhuis CK, Hoefnagel CA, Voƻte PA, Smets LA.

Int J Cancer. 2000 Aug 1;87(3):412-22.

8.

Hepatic absorbed radiation dosimetry during I-131 metaiodobenzylguanidine (MIBG) therapy for refractory neuroblastoma.

Koral KF, Huberty JP, Frame B, Matthay KK, Maris JM, Regan D, Normolle D, Yanik GA.

Eur J Nucl Med Mol Imaging. 2008 Nov;35(11):2105-12. doi: 10.1007/s00259-008-0873-3. Epub 2008 Aug 6.

PMID:
18682939
9.

Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.

Cunningham SH, Mairs RJ, Wheldon TE, Welsh PC, Vaidyanathan G, Zalutsky MR.

Br J Cancer. 1998 Jun;77(12):2061-8.

10.

The distribution of alternative agents for targeted radiotherapy within human neuroblastoma spheroids.

Mairs RJ, Angerson W, Gaze MN, Murray T, Babich JW, Reid R, McSharry C.

Br J Cancer. 1991 Mar;63(3):404-9.

11.

The treatment of resistant neuroblastoma with 131I-mIBG: alternative methods of dose prescription.

Fielding SL, Flower MA, Ackery DM, Kemshead J, Lashford LS, Lewis IJ.

Radiother Oncol. 1992 Sep;25(1):73-6.

PMID:
1410594
12.

Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and perspectives.

Beierwaltes WH.

Med Pediatr Oncol. 1987;15(4):188-91.

PMID:
3657705
13.

Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.

Madsen MT, Bushnell DL, Juweid ME, Menda Y, O'Dorisio MS, O'Dorisio T, Besse IM.

J Nucl Med. 2006 Apr;47(4):660-7.

14.

Local delivery of (131)I-MIBG to treat peritoneal neuroblastoma.

Kinuya S, Li XF, Yokoyama K, Mori H, Shiba K, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N.

Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1246-50. Epub 2003 Jun 17.

PMID:
12811531
15.

Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.

Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H.

Nuklearmedizin. 2006;45(4):145-51; quiz N39-40.

PMID:
16964339
16.

Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.

Mairs RJ, Russell J, Cunningham S, O'Donoghue JA, Gaze MN, Owens J, Vaidyanathan G, Zalutsky MR.

Eur J Cancer. 1995;31A(4):576-81.

PMID:
7576972
17.

Radiation dosimetry for 131I-mIBG therapy of neuroblastoma.

Flower MA, Fielding SL.

Phys Med Biol. 1996 Oct;41(10):1933-40.

PMID:
8912372
18.

[Diagnosis and therapy of neuroectodermal tumors].

Adolph J, Kimmig B.

Radiologe. 1989 Jan;29(1):32-42. German.

PMID:
2537501
19.

Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.

Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM.

J Clin Oncol. 2009 Mar 1;27(7):1020-5. doi: 10.1200/JCO.2007.15.7628. Epub 2009 Jan 26.

20.

Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results.

Buckley SE, Saran FH, Gaze MN, Chittenden S, Partridge M, Lancaster D, Pearson A, Flux GD.

Cancer Biother Radiopharm. 2007 Feb;22(1):105-12.

PMID:
17627418

Supplemental Content

Support Center